No Data
No Data
Arcutis Surges 18% as Mizuho Highlights Growth of Zoryve
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $12 to $20
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session